Table 2.
Prognostic factors and the development of liver metastasis—all cohorts.
| Univariable Cox regression analysis | Multivariable Cox regression analysis | |||||
|---|---|---|---|---|---|---|
| N (%)a | HR (95%CI)b | P | N (%)a | HR (95%CI)b | P | |
| sCD40 | 389 (98) | 1.002 (1.001–1.002) | <0.001 | 233 (59) | 1.001 (1.000–1.002) | 0.006 |
| CEA | 326 (83) | 0.999 (0.987–1.011) | 0.892 | 233 (59) | 0.988 (0.966–1.010) | 0.280 |
| TRG | 286 (72) | 1.844 (1.246–2.729) | 0.002 | 233 (59) | 1.781 (1.028–3.084) | 0.039 |
| ypT | 286 (72) | 1.838 (1.270–2.661) | 0.001 | 233 (59) | 1.522 (0.966–2.399) | 0.070 |
CEA carcinoembryonic antigen, CI confidence interval, HR hazard ratio, sCD40 soluble cluster of differentiation molecule 40, TRG tumour regression grade, ypT histologic tumour stage following neoadjuvant treatment.
aPatients who developed lung metastasis (six cases) before the first occurrence of liver metastasis were omitted from the analysis.
bHR above 1 indicates enhanced probability for the event.